Autolus Therapeutics (AUTL) Other Non Operating Income (2017 - 2025)
Autolus Therapeutics (AUTL) posted quarterly Other Non Operating Income of $400000.0 for Q4 2025, down 96.49% year-on-year from $11.4 million in Q4 2024, and up 143.91% on a QoQ basis from -$911000.0 in Q3 2025.
Autolus Therapeutics (AUTL) Other Non Operating Income (2017 - 2025) Analysis & Trends
Autolus Therapeutics (AUTL) has reported Other Non Operating Income for 9 consecutive years, with $400000.0 the latest figure, recorded in Q4 2025.
- Quarterly Other Non Operating Income fell 96.49% year-over-year to $400000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.2 million (up 461.82% YoY) and the FY2025 annual result came in at $2.2 million, up 320.0% from the prior year.
- Other Non Operating Income grew to $400000.0 in Q4 2025 per AUTL's latest filing, from -$911000.0 in the prior quarter.
- Over the last five years, Other Non Operating Income for AUTL reached as high as $11.4 million in Q4 2024 and fell as low as -$11.9 million in Q3 2024.
- A 5-year average of $304550.0 and a median of $632000.0 in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2022 — Other Non Operating Income jumped 7369.77% — and 2024, when it slumped 586.67%.
- Year by year, Other Non Operating Income stood at -$86000.0 in 2021, then soared by 7369.77% to $6.3 million in 2022, then slumped by 50.72% to $3.1 million in 2023, then surged by 270.01% to $11.4 million in 2024, then plunged by 96.49% to $400000.0 in 2025.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $400000.0, -$911000.0, and $1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - |
| 3 | Akari Therapeutics | 1,023.69 Bn | 1,023.69 Bn | - |
| 4 | BeOne Medicines | 468.59 Bn | 463.80 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.01 Bn | 115.76 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.29 Bn | 61.53 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.33 Bn | 63.33 Bn | - |
| 8 | Argenx Se | 55.70 Bn | 50.52 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.79 Bn | 34.78 Bn | 959.66 Mn |
| 10 | Autolus Therapeutics | 395.22 Mn | 94.51 Mn | -1.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 400,000.00 |
| Sep 30, 2025 | -911,000.00 |
| Jun 30, 2025 | 1.50 Mn |
| Mar 31, 2025 | 1.20 Mn |
| Dec 31, 2024 | 11.40 Mn |
| Sep 30, 2024 | -11.90 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | -1.31 Mn |
| Dec 31, 2023 | 3.08 Mn |
| Sep 30, 2023 | -1.73 Mn |
| Jun 30, 2023 | 482,000.00 |
| Mar 31, 2023 | 782,000.00 |
| Dec 31, 2022 | 6.25 Mn |
| Sep 30, 2022 | -3.74 Mn |
| Jun 30, 2022 | -1.33 Mn |
| Mar 31, 2022 | 860,000.00 |
| Dec 31, 2021 | -86,000.00 |
| Sep 30, 2021 | 951,000.00 |
| Jun 30, 2021 | -1.85 Mn |
| Mar 31, 2021 | 838,000.00 |